Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 10Esophageal Squamous Cell Carcinoma 4Carcinoma, Hepatocellular 4Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Pancreatic Neoplasms 2Head and Neck Neoplasms 2HER2-positive Gastric Cancer 2Colonic Neoplasms 2Breast Neoplasms 2Stage IA Pancreatic Adenocarcinoma 1Mouth Neoplasms 1Malignant Neoplasms of Digestive Organs 1Immunotherapy 1Gastric Adenocarcinoma 1Gallbladder Neoplasms 1Fruquintinib 1For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method 1Extrapancreatic Neuroendocrine Tumor 1Esophageal Neoplasms 1Efficacy and Safety 1Drug-Related Side Effects and Adverse Reactions 1Biliary Tract Neoplasms 1Advanced Pancreatic Cancer 1Advanced Biliary Tract Carcinoma 1Adenoma, Islet Cell 1Adenocarcinoma 1

Interventions

Trastuzumab 3disitamab vedotin 2Tegafur 2Oxaliplatin 2tucatinib 1tislelizumab 1S 1 (combination) 1Ramucirumab 1Paclitaxel 1Drug Therapy 1Capecitabine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × HER2-positive Gastric Cancer × Tegafur × Clear all
NCT06439550 2024-06-03

Adjuvant Treatment With Serplulimab,Trastuzumab and SOX in the HER-2 Positive GC/GEJC

The First Affiliated Hospital of Zhengzhou University

Phase 2 Not yet recruiting
42 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT05070598 2021-10-07

Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer

Shengjing Hospital

Phase 2 Unknown
35 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡